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Résumé 
Un  remodelage vasculaire anormal est à la base de la pathogenèse des maladies 
cardio-vasculaires (MCV) telles que l’athérosclérose et l’hypertension. Des 
dysfonctionnements au niveau de la migration, l’hypertrophie et la prolifération des 
cellules musculaires lisses vasculaires (CMLV) sont des évènements cellulaires qui 
jouent un rôle primordial dans le remodelage vasculaire. L’insulin-like growth factor 1 
(IGF-1), puissant facteur mitogène, contribue au développement des MCV,  notamment 
via l’activation des protéines MAPK et PI3-K/PKB, composantes clés impliquées dans 
les voies de croissance cellulaire. Ces molécules sont également impliquées dans la 
modulation de l’expression de nombreux facteurs de transcription, incluant le facteur 
Egr-1. Egr-1 est régulé à la hausse dans différents types de maladies vasculaires 
impliquant les voies de signalisation de croissance et de stress oxydant qui par ailleurs 
peuvent être déclenchées par l’IGF-1. Cependant, la question d’une possible modulation 
de l’expression d’Egr-1 dans les CMLV demeure inabordée; plus spécifiquement, la 
caractérisation de la voie de signalisation reliant l’action d’IGF-1 à l’expression d’Egr-1 
reste à établir. Dans cette optique, l’objectif de cette étude a été d’examiner l’implication 
de MAPK, PKB et des dérivés réactifs de l’oxygène (DRO) dans l’expression d’Egr-1 
induite par l’IGF-1 dans les CMLV. L’IGF-1 a induit une augmentation marquée du 
niveau protéique de l’Egr-1 en fonction du temps et de la concentration utilisés. Cette 
augmentation a été inhibée en fonction des doses d’agents pharmacologiques qui ciblent 
les voies de signalisation de MAPK, PKB et DRO. De plus, l’expression du facteur de 
transcription, Egr-1, en réponse de l’IGF-1, a été atténuée suite à un blocage 
pharmacologique des processus cellulaires responsables de la synthèse d’ARN et de 
synthèse protéique. Pour conclure, on a démontré que l’IGF-1 stimule l’expression 
d’Egr-1 via les voies de signalisation, impliquant ERK1/2/JNK, PI3K/PKB. On a 
également proposé que les DRO jouent un rôle important  dans ce processus. Dans 
l’ensemble, nous avons suggéré un nouveau mécanisme par lequel l’IGF-1 promeut la 
prolifération et l’hypertrophie cellulaire, processus à la base des anomalies vasculaires.  
Mots-clés : Egr-1, IGF-1, IGF-1R, ERK1/2, JNK, PKB, PI3-K, CMLV. 
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Abstract 
Aberrant vascular remodelling underlies the pathogenesis of major 
cardiovascular diseases (CVD), such as atherosclerosis and hypertension. Abnormal 
growth, migration and proliferation of vascular smooth muscle cells (VSMC) are 
believed to play a critical role in vascular remodelling.  IGF-1, potent mitogen, is 
believed to contribute to the development of CVD through the hyperactivation of 
proliferative and growth promoting pathways including mitogen-activated protein kinase 
(MAPK) and protein kinase B (PKB) pathways. It has also been implicated in 
modulating the expression of multiple transcription factors, including the early growth 
response protein-1 (Egr-1). Egr-1 upregulation has been observed in different models of 
vascular diseases implicating growth and redox signalling such as observed in response 
to IGF-1. However, modulation of Egr-1 expression by IGF-1 in VSMC, more 
specifically the signaling pathways involved in this process remain poorly characterized. 
Therefore, in the present studies, we investigated the implication of MAPK, PKB and 
ROS in IGF-1-induce Egr-1 expression in VSMC. IGF-1 induced a marked increase in 
Egr-1 protein level in a time and dose-dependent fashion. This increase was dose 
dependently inhibited by different pharmacological inhibitors targeting MAPK, PKB 
and reactive oxygen species (ROS) generation. Furthermore, pharmacological inhibitors 
of RNA and protein synthesis also attenuated IGF-1-induce response on Egr-1 
expression. In conclusion, we showed that IGF-1 stimulates the expression of Egr-1 
through ERK1/2/JNK and PI3K/PKB. We also propose that ROS generation plays an 
important role in this response. Overall, we propose a novel mechanism through which 
IGF-1 may exert its deleterious responses in vascular abnormalities.   
Keywords: Egr-1, IGF-1, IGF-1R, ERK1/2, JNK, PKB, PI3-K, VSMC.  
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INTRODUCTION 
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Cardiovascular diseases (CVD) are the primary cause of mortality and morbidity globally 
(1). The biology of CVD is very complex, however remodelling of blood vessels has been 
suggested to play an important role in the pathogenesis of CVD. Vascular smooth muscle 
cells (VSMC) are highly specialized cells that line the blood vessels and contribute to 
vessel contraction by regulating vascular tone and blood pressure (2, 3). Abnormal growth, 
migration and proliferation of VSMC are believed to be key events in vascular remodelling 
and have been implicated in the pathogenesis of vascular disease such as intimal 
hyperplasia, hypertension, atherosclerosis and restenosis (4, 5). During these 
pathophysiological states, there is an increased expression in activity of vasoactive peptides 
and growth factors such as insulin-like growth factor 1 (IGF-I) that are implicated to induce 
proliferation, hypertrophy, migration, apoptosis and differentiation in VSMC by structural 
alterations in the vessel wall (6-9). IGF-1 is a potent mitogen for VSMC and a potential 
pathogenic role of IGF-1/insulin-like growth factor 1 receptor (IGF-1R) system in vascular 
dysfunction has been suggested (10). A significantly higher level of IGF-1R and signaling 
has been reported in the VSMC isolated from the aorta of hypertensive animal models (11-
13). In addition, dominant-negative or antisense oligonucleotides of IGF-1R were also 
shown to attenuate neointimal thickening in injured carotid arteries (13, 14). Thus, IGF-
1/IGF-1R system via activation of growth promoting proliferative signaling pathways and 
gene expression has emerged as a key molecule involved in the pathogenesis of vascular 
disease. The following sections describe the structure and function of IGF-I as well as IGF-
1-induced signaling pathways that trigger various responses of IGF-1 in VSMC.  
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1.1. IGFs system 
IGFs play a fundamental role in the regulation of key cellular and physiological 
processes such as development, growth, cellular regulation and metabolism in mammals. 
Originally, IGFs were named sulphation factors by Salmon and Daughaday in 1957, 
because of their capacity to incorporate sulphate into cartilage (15). In 1972, a more 
intensive research of these factors proposed a new nomenclature, identifying two different 
types of peptides: somatomedin C and somatomedin A that mediate the effects of growth 
hormone (GH) (16). Finally, in 1978, Rinderknecht and Humbel found many resemblances 
between somatomedins and insulin in amino acid sequence and metabolic functions. 
Therefore, peptides were renamed IGF-1 and 2 (17). IGFs system consists of two ligands 
with similar structure: IGF-1 and IGF-2; three cell-membrane receptors IGF-1R and IGF-
2R and insulin receptor (IR); and a family of 6 high affinity insulin-like growth factor 
binding proteins (IGFBPs 1-6). 
1.2 IGFs protein and gene structure 
IGF-1 and IGF-2 each consist of a single chain of 70 and 67 amino acid polypeptides 
hormone with molecular weights of 7.6kDA and 7.4kDA respectively (Figure 1.1). Three 
dimensional structure of IGF-1 by nuclear magnetic resonance (NMR) and X-ray 
crystallography methods have been reported by several groups. However, IGF-2 structure 
has been less studied; therefore only two NMR structures have been reported to date. Three 
intramolecular disulphide bonds, formed by conserved cysteine residues, hold the IGFs 
structure (IGF-1 residues: Cys6-Cys48, Cys18-Cys61, Cys47-Cys52) together and consist 
of A, B, C and D domains. An A domain of 21 residues, contains alpha helix 2 (Ile43-
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Cys47 of IGF-1; Glu44-Phe48 of IGF-2) and alpha helix 3 (Leu54-Glu58 of IGF-1; Ala54-
Tyr59 of IGF-2) joined by a loop, and B domain of 29 residues, with an extended N-
terminal coil followed by a tight turn and a central alpha helix1 (Gly8-Cys18 of IGF-1; 
Gly10-Val20 of IGF-2), both forming hydrophobic core. IGFs possess the C peptide region 
of 12 amino acids that is an active part of the IGFs and an 8-amino acid carboxyterminal D 
domain (17, 18).  
IGF-1 is the product of Igf1 gene that is situated on the long arm of chromosome 12. It 
is a single copy gene consisting of 2 precursor peptides, 153-amino acid IGF-1A and 195-
amino acid IGF-1B. Two separate mRNAs produced by alternative splicing of the primary 
gene transcript are necessary to synthesise these 2 peptides. On the other hand, IGF-2 gene 
is found on chromosome 11. The 180-amino acid IGF-2 preprohormone contains a 
carboxy-terminal peptide of 89 amino acids and a signal peptide of 24 amino acids, both of 
which are cleaved post-translationaly to produce 67-amino acid plasma protein (19).  
 
Figure 1.1 Structure of insulin-like growth factor-1 (IGF-1) amino acid sequence.  
IGF-1 is a single copy of 70 amino acid cyclic protein with three disulphide bridges linked 
by cysteine residues. (Based on ref. (20)).  
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1.3 IGF-1 synthesis and regulation  
Igf-1 gene consists of 6 exons and 5 introns. IGF-1 synthesis occurs primarily in the 
liver and its plasma concentration is regulated by liver GH; however the ability of GH to 
stimulate IGF-1 is dependent on nutritional status. Once synthesised and released in the 
circulation, IGF-1 can be found in a free form or mainly bound to IGFBPs. Genetic factors 
and age are also important determinants that control the variability of serum IGF-1 
concentrations. Other hormones, including cortisol, oestradiol, thyroxine and testosterone 
interact with GH in regulating hepatic IGF-1 synthesis (21). It has been shown that IGF-1 
synthesis also occurs in numerous peripheral tissues, such as skeletal muscle, bone and 
cartilage, acting locally as autocrine/paracrine or endocrine factors that circulate in the 
plasma in order to regulate cell growth (22). Normal plasma IGF-1 concentration is 
maintained through the negative-feedback mechanism by supressing GH synthesis in the 
pituitary gland. Two promoters P1, (expressed in all tissues) and P2 (primarily expressed in 
the liver), initiate the IGF-1 mRNA transcription containing exon 1 and exon 2, 
respectively (23). 
In addition, in cardiovascular system, IGF-1 is also secreted and synthesized by 
vascular cells. There is evidence of three IGF-1 mRNA transcripts sized 8.2, 1.7, and 0.9-
1.2kb that have been localized in smooth muscle cells of adult rat aorta and two IGF-1 
transcripts of 2.1 and 1.6 kb expressed in aortic endothelial cells. IGF-1 is also secreted by 
both endothelial cells (EC) and VSMC and regulated by growth factors, vasoactive peptides 
and hormones (24, 25). 
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1.4 IGF-1 protein processing 
IGF-1 processing leading to mature IGF-1 protein begins with IGF-1 gene 
translation into a Pre-pro-IGF-1 precursor protein, which consists of a signal peptide, signal 
peptide cleavage site, mature IGF-1, pro-protein convertase cleavage site and C-terminal E-
peptide extension (26) (Figure 1.2). During translation in the endoplasmic reticulum (ER), 
the N-terminal signal peptide is cleaved, resulting in pro-IGF-1 polypeptide (mature IGF-1 
and E-peptide) that can be differently processed before secretion. This processing includes 
Pro-IGF-1 intracellular protease cleavage separating the mature IGF-1 for secretion from 
free E-peptide, maintenance of pro-IGF-1 to be secreted without cleavage, or N-
glycosylation in the E-peptide, and then secretion. Thus, there are three different forms of 
IGF-1 protein, which are: mature IGF-1, glycosylated-pro-IGF-1 and nonglycosylated-pro-
IGF-1 (27, 28).  
 
Figure 1.2 Insulin-like growth factor-1 (IGF-1) processing leading to mature IGF-1.  
The Igf1 gene is first translated into a Pre-pro-IGF-1 precursor protein that includes a signal 
peptide, signal peptide cleavage site, IGF-1, pro-protein convertase site, and E-peptide. 
During translation, the signal peptide is removed from the remaining protein, now called 
Pro-IGF-1. Further protease cleavage separates the mature IGF-1 from free E-peptide. 
While mature IGF-1 has many accepted growth effects on a wide variety of cells and 
tissues, the purpose and actions of the E-peptide are relatively unknown. (Brisson BK., and 
Barton ER.,: Front Endocrinol. 27: 42, 2013). 
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1.5 IGFBPs 
The level of free IGFs in the circulation is regulated by a family of IGFBPs, 
consisting of six members (IGFBP-1 to IGFBP-6) and found in all extracellular biological 
fluids. IGFBPs act as transporters of IGF, therefore prolonging their half-life and control 
free IGF availability in the circulation. IGFBPs also act as inhibitors by sequestrating IGF 
from its receptor and as a promoter by increasing IGF-IGFR interaction (29). Other 
important role of IGFBPs independent of IGF-binding, include their direct association with 
many extracellular and cell surface molecules (30). In extracellular fluids, 99% of IGF-1 is 
bound with high affinity to IGFBPs and only less than 1% of total amount of IGF is in an 
unbound form (31). In tissues, IGF-1 and IGF-2 form binary complexes with different type 
of IGFBPs. In the circulation, IGFBPs are found as ternary complexes of 150 kDa 
consisting of IGF, predominantly of IGFBP-3 or a fraction of IGFBP-5 and an 85 kDa 
liver-derived glycoprotein (acid-labile subunit, ALS). The ternary complex occurs in the 
liver where the IGF-1 and ALS are derived from the hepatocyte and IGFBP-3 is produced 
in the Kupffer cells (32, 33). These complexes prolong the circulating IGF-1 half-life, from 
less than 15 min up to 16 hours. They have limited ability to cross the capillary endothelial 
barrier, therefore maintaining a large circulating reservoir of IGF which can be then 
available to the tissues (34). In contrast to ternary complexes, some members of IGFBP 
family (IGFBP-1,-2,-4 and -5) also form binary complexes of 50kDa in plasma that are 
incompletely saturated with IGF, therefore permeable to vascular endothelium (29). It has 
been shown that post-translational IGFBP modifications, including proteolysis, 
phosphorylation and glycosylation, have the ability to alter the IGF-binding affinity (35).  
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IGFBPs share a highly conserved structure consisting of three domains: N-terminal (80-93 
amino acid residues) and C-terminal domains (65 amino acid residues), both cysteine rich, 
and the highly variable central domain (55 amino acid residues). The N-terminal and C-
terminal domains participate in IGF-binding, whereas, the central domain is unique to all 
IGFBPs. It acts as a hinge between N- and C-terminal domains where occurs most of post-
translational modifications and proteolytic cleavage, resulting in loss of IGF-binding (32). 
In addition to IGFBP similarities, some structural differences have been described. It 
appears that only eight disulphide bonds are present in IGFBP-6 compared with nine in the 
other members of IGFBPs family (32).  
1.6 IGF-1 receptor 
IGF-1 exerts its biological actions through its interaction with a specific high 
affinity IGF-1R (25). IGF-1R is a 1367 amino acids heterotetrameric cell-surface 
glycoprotein that is synthesized as a 30 residue single polypeptide chain preproreceptor and 
is cleaved post translationally to pro-receptor. The proreceptor forming disulphide-linked 
dimers is then glycosylated, folded and dimerized by chaperones, calnexin and calreticulin 
(36) and transported to the Golgi apparatus to yield mature receptor consisting of two alpha 
(1-707 residues) and beta subunits (712-1337 residues) (37). The mature IGF-1R has a 
similar biochemical structure as IR and belongs to a large family of receptor-protein 
tyrosine kinases (R-PTK). IGF-1R is composed of 3 domains: the N-terminal extracellular 
hormone-binding domain, a transmembrane region and the C-terminal intracellular domain 
with intrinsic kinase activity and regulatory residues (38). The alpha subunit and 194 
residues of beta subunit are located in N-terminal part of IGF-1R and include 11 potential 
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N-linked glycosylation sites (Asn-X-Ser/Thr motifs) and also consist of two homologous 
leucine-rich domains (L1 and L2) separated by a cysteine-rich region (39). The beta subunit 
comprise three fibronectin type III domains (FnIII-1 residues 461-579, FnIII-2 580-798 and 
FnIII-3 799-901) (40), followed by tyrosine kinase catalytic domain (973-1255 residues). 
The tyrosine kinase domain is flanked by 2 regulatory regions: a juxtamembrane site (Asn-
Pro-X-Tyr motifs) involved in docking of insulin receptor substrates (IRS), Src homology 
collagen (Shc) and internalization of the receptor (41), and also a 108-residue carboxy-
terminal tail (Gly-X-Gly-X-X-Gly motifs) that contains the phosphotyrosine binding sites, 
therefore contributing to IGF-1R activation (41, 42) (Figure 1.3). 
 In addition to IGF-1, IGF-2 exerts its physiological effects by binding to IGF-2R, 
also called mannose-6-phosphate-receptor (M6P-R).  IGF-2R is a single cell-surface 
receptor with no PTK activity, containing 4 structural domains: the amino-terminal signal 
sequence, the extracytoplasmic domain, the transmembrane region and the carboxy-
terminal tail (43). The IGF-2R participates in clearing IGF-2 from the cell surface by 
internalization and lysosomal degradation, therefore decreasing its mitogenic effects (29). It 
also has been shown that IGF-2R exists as a cleaved form in circulation, therefore is able to 
act as an IGFBP for IGF-2 protein (44).  
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Figure 1.3 Schematic representation of Insulin-like growth fcator-1 (IGF-1). 
Secondary structure of IGF-1R demonstrates the location of different domains in α and β 
subunits that are linked with disulphide bonds. (Adapted from Gatenby et al: Pflugers Arch 
465: 1065-1074, 2013). 
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1.7 IGF-1 signaling in vascular system  
IGF-1 exerts its physiological effects through the activation of IGF-1R via multiple 
signaling cascades, including the mitogen activated protein kinase (MAPK) and 
phophatidyl-inositol 3-kinase/protein kinase B (PI3-K/PKB) cascade (45). The activation of 
these pathways is implicated in many cellular processes such as cell growth, proliferation, 
migration and survival of VSMC (25, 46, 47). IGF-1 binding to the extracellular IGF-1R 
alpha subunit results in conformational changes, leading to subsequent trans-
autophophorylation of intrinsic tyrosine residues, Tyr 1131, 1135 and 1136 of IGF-1R beta-
subunit, evoking an increased tyrosine kinase activity of the receptor (48). The first step in 
signal transduction by IGF-1R is the phosphorylation of several cytosolic receptor 
substrates, including IRS 1-4 and adaptor protein Shc, that serve as docking sites for Src 
homology 2 (SH2) domain-containing proteins, such as growth factor receptor-binding 
protein 2 (Grb-2), guanine nucleotide exchange factor son of sevenless (SOS), Nck and p85 
regulatory subunit of PI3-K (49).  
One of signaling cascades that emerges following IGF-1R activation involves 
MAPK pathway. MAPK are a group of serine-threonine kinases that has been closely 
associated with cell migration, proliferation and differentiation and also plays an important 
role in apoptosis (50). In mammalian cells, 5 members of the MAPK family have been 
described, including extracellular signal regulated kinases 1 and 2 (ERK1/2), also known as 
p42/44 as MAPK, Jun N-terminal kinase 1, 2 and 3 (JNK1/2/3), also called stress-activated 
protein kinase (SAPK), p38, ERK5 and ERK7 (51, 52). The most studied members of 
MAPK class to date are ERK1/2, JNK and p38α/β/γ/δ (48). IGF-1-induced ERK1/2 
activation is initiated by the recruitment of Grb-2/SOS complex on the phosphorylated IRS 
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or adaptor protein Shc leading to the activation of guanosine triphosphate (GTP)-binding 
protein Ras, by exchanging the small guanosine diphosphate (GDP) to GTP. This process 
initiates sequential phopsphorylation by recruiting serine-threonine kinase Raf (A-Raf, B-
Raf and C-Raf) to the membrane, after activating MAP kinase kinase 1 and 2 (MEK1 and 
MEK2) and MAP kinase (ERK1/2) in Thr and Tyr within a conserved Thr-Glu-Tyr  motif 
in their activation  loop (49, 53, 54). Activation of ERK1/2 can either phosphorylate and 
stimulate a number of cytosolic proteins, or translocate to the nucleus and activate several 
transcription factors, such as ETS domain-containing protein Elk-1 (Elk1), SRF, ATF2 and 
Jun implicated in immediate early gene transcription (55).  
A second well-known pathway that is triggered following IGF-1R activation in 
vascular system involves another SH2 domain-containing protein, the p85 regulatory 
subunit of PI3-K (56-58). Interaction of p85 with the phosphorylated IRS leads to the 
activation of catalytic subunit of PI3-K, p110. Activated PI3-K catalyzes the conversion of 
phosphatidylinositol 4, 5-bisphosphate (PI(4,5)P2) to phosphatidylinositol 3, 4, 5-
trisphosphate (PI(3, 4,5)P3), which is a key signaling molecule and an important second 
messenger that recruits cytosolic proteins with pleckstrin-homology (PH) domain such as 
serine-threonine PKB and phosphoinositide-dependent kinase 1 and 2 (PDK1/2) (59). PKB 
is phosphorylated in the activation loop of its catalytic domain on Thr308 and in the C-
terminal domain on Ser473 by PDK1/2 respectively (60, 61). PKB has multiple 
downstream targets, such as mammalian target of rapamycin (mTOR) implicated in protein 
synthesis, p70 ribosomal S6 kinase (p70s6k), forkhead box protein (FOXO), glycogen 
synthase kinase-3 (GSK-3) and also triggers anti-apoptotic effects trough the 
phosphorylation of  Bcl-2-associated death promoter (Bad) (62, 63).  
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It has been also shown that IGF-1R can signal via Janus kinases-1/2/3/signal 
transducers and activators of transcription (JAK-1,2,3/STAT) pathway, activated by 
cytokines and growth factors, depending on the cell type (64). Cell proliferation, 
differentiation, death and embryonic development are the cellular events that are regulated 
by the JAK/STAT pathway. The activated IGF-1R/JAK complex serves as a docking site 
for the recruitment of specific SH-2 domain-containing STAT proteins, resulting in STAT 
homodimerization and translocation to the nucleus acting as transcription factors (65).  
1.8 Biological actions of IGF-1 in vascular system  
In vasculature, IGF-1 exerts pleiotropic actions. In fact, a number of studies 
supported the concept that IGF-1 is a potent mitogen that plays a permissive role in 
vascular dysfunction, because of its pro-atherogenetic properties that contribute to VSMC 
proliferation and migration, thereby promoting neointima formation (66, 67). IGF-1 has 
also been shown to enhance chemotactic macrophage migration (68) and promote cell 
adherent molecule expression leading to the development of cardiovascular disease, such as 
atherosclerosis (69, 70). However, IGF-1 has also been suggested to serve as a vascular 
protective factor. There is increasing evidence suggesting a role of IGF-1 in endothelial 
repair and regulation of vascular tone under pathological conditions. IGF-1 has been shown 
to induce vasorelaxation through the regulation of nitric oxide (NO) (an important 
vasoprotective factor in cardiovascular homeostasis) production via the stimulation of 
inducible NO synthase (iNOS) in VSMC as well as the activation of endothelial nitric 
oxide synthase (eNOS) in EC (71). This hypothesis has been supported by the F. Perticone 
group, where endothelial dysfunction, as illustrated by aberrant vasodilatory properties, was 
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associated with low IGF-1 levels (72). In fact, IGF-1 supplementation in diabetic patients, 
characterized by impaired vascular tone, improves vasodilatory responses mainly by 
increasing eNOS activity (69). Several in vivo and in vitro studies have shown that in the 
presence of low levels of IGF-1, the contracted aortic rings stimulated with norepinephrine 
undergo vasorelaxation, whereas, the high levels of IGF-1 are able to induce a complete 
vasodilation in coronary artery (73). Experiments using a pharmacological inhibitor of NO 
synthase, Nω-nitro-L-arginine methyl ester (L-NAME), has attributed the vasodilatory 
properties of IGF-1 to its ability to induce NO production, suggesting that IGF-1 acts on 
vascular tone via endothelial NO stimulation (74, 75). In EC, recent publications have 
demonstrated that IGF-1 increased eNOS dependent NO production through the activation 
of PI3K/PKB pathways involving Ser1177 residue phosphorylation (69, 76). Moreover, in 
healthy human vessels, IGF-1 infusion has also been found to induce vasorelaxation 
through the activation of potassium channels that leads to a decrease in intracellular 
calcium (77). The contribution of IGF-1 in NO production has also been observed in 
endothelial progenitor cells (EPC) know to be important for endothelial repair. In fact, 
following IGF-1 administration in human subjects, an increased number of EPC was 
observed and associated with NO bioavailability (78).  In addition to its effects on vascular 
tone, IGF-1 plays an important role in arterial tone and vascular resistance by increasing 
blood flow and lowering blood pressure. In vivo studies, Pete G., et al have shown that 
exogenous IGF-1 administration in Wistar rats resulted in a decrease of blood pressure and 
an increase of blood flow (75). The role of endogenous IGF-1 has also been documented in 
cardiovascular physiology. In 4 month old liver-derived IGF-1 knock-out (LI-IGF-1-/-) 
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mice model that is characterized with low serum IGF-1 level; systolic blood pressure was 
significantly increased (79). 
IGF-1 is commonly considered as a potent mitogen with growth promoting and 
proliferative properties on VSMC that contribute in the process of restenosis after balloon 
injury and activation of IGF-1R triggers signaling pathways leading to VSMC apoptosis. In 
fact, the group of Lim has shown that dominant negative IGF-1R inhibits VSMC 
proliferation and neointimal formation through its proapoptotic actions in rat injured carotid 
arteries (14). Increased VSMC apoptosis contribute to the structural degeneration of media 
layer and therefore, leads to intimal thickening (80). Some studies suggest that poor 
expression of IGF-1 and IGF-1R in intimal layer would likely contribute to an excessive 
loss of VSMC, which is considered as a hallmark of advanced destabilized atherosclerotic 
plaques (81, 82). Conversely, it has also been postulated that high levels of IGF-1 
contributes to the structural integrity of the fibrous cap and by acting as a potent survival 
factor preventing apoptosis of VSMC.  VSMC accumulation in return may act as a vascular 
repair mechanism. Therefore, this protective role of IGF-1 may be beneficial for 
stabilization of the atherosclerotic plaque in the early stage of atherosclerosis (83, 84). 
It has been also documented that in vascular system, IGF-1 can exert anti-
inflammatory and antioxidant properties by mainly modulating cytokine responses, as well 
as by upregulating eNOS activity. It has been shown that the infusion of IGF-1 in the aorta 
of ApoE-nulle mice reduced macrophage infiltration within atherosclerotic lesions, 
decreased aortic expression of pro-inflammatory cytokines and increased levels of 
circulating ECP. Furthermore, IGF-1 suppressed vascular superoxide levels via an increase 
in eNOS activity and NO bioavailability in the same model (85, 86). In vitro study, using 
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cultured human aortic EC, has also reported that IGF-1 has potent endothelial antioxidant 
effects on both basal and oxidized LDL-induced reactive oxygen species (ROS) generation. 
This activity is mainly mediated through the upregulation of glutathione peroxidase-1 
(GPX-1) expression and its activity (87). Yet, in contrast to the anti-inflammatory and 
antioxidant effects of IGF-1, a large body of evidence suggests that IGF-1 has pro-
inflammatory activity. For instance, in vitro study, using monocytes/macrophages, IGF-1 
has been shown to induce the release of pro-inflammatory cytokines, such as tumour 
necrosis factor-α (TNF-α), that may play a role in plaque growth and disruption and also to 
enhance chemotactic macrophage migration in atherosclerosis (88). In addition, it has been 
shown that IGF-1 and ROS generation co-ordinately enhance VSMC growth leading to 
atherosclerotic process. This is demonstrated by the ability of IGF-1 to increase ROS 
generation in VSMC and possibly amplify its activity via ROS activation (89, 90). To 
further clarify IGF-1 beneficial or harmful actions on inflammatory responses, oxidative 
stress, atherosclerotic plaque development and endothelial dysfunction in vascular system, 
additional studies are needed.  
IGF-1 has been also shown to play an important role in the regulation of cardiac 
function. IGF-1 and its receptor are found in fetal and adult rat cardiomyocytes where they 
play a critical role during embryological development. In cultured rat cardiomyocytes, IGF-
1 has been shown to directly induce cardiac hypertrophy through PI3-K/ERK pathways. 
Activation of these intracellular signaling cascades may be directly associated with 
elevation of intracellular calcium (Ca2+) concentration, therefore may induce myocardial 
contractility (91). In fact, several studies attributed the involvement of IGF-1 in activation 
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of contractile proteins such as actin, myosin light chain-2, troponin I, β-myosin heavy chain 
and skeletal α-actin in neonatal rat cardiac myocytes (92). IGF-1 also play a role in 
decreasing protein degradation and participates in early neonatal cardiomyocyte 
proliferation and maturation (93). In myocardial ischemia followed by reperfusion injury, 
administration of IGF-1 in animals seems to be cardioprotective; it improves cardiac 
performance during reperfusion and improves post-ischemic recovery in hypertrophied 
hearts (94). IGF-1 may also act as an anti-apoptotic factor by decreasing the number of 
apoptotic cardiomyocytes through the activation of B-cell lymphoma 2 (Bcl-2) pathways 
(93). The loss of cardiomyocytes results in heart failure (93). 
1.9 IGF-1 in cardiovascular pathophysiology  
In the vasculature, a significant decrease in IGF-1 level could be beneficial in 
certain pathological states, including the early stage of atherosclerotic plaque formation. 
However, over the last years, numerous studies have correlated low circulating IGF-1 levels 
with an increased risk for cardiovascular disease, such as atherosclerosis, coronary artery 
diseases, ischemic heart disease and hypertension (71, 95-98). 
1.9.1 IGF-1 in atherosclerosis  
Atherosclerosis is an inflammatory process, where VSMC proliferation and 
migration to the intima layer is a major pathological vascular action resulting in neointima 
formation and therefore development of atherosclerotic lesions (6). Evidence supporting a 
role for IGF-1 in the pathogenesis of atherosclerosis comes from the data supporting that 
IGF-1 and its receptor expression are markedly increased in human atherosclerotic plaques, 
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including VSMC (99). Accumulating evidence indicates that IGF-1 has been considered to 
contribute to the development of atherosclerosis via its ability to stimulate VSMC 
migration and proliferation (81). In fact, studies exploring mechanical injury models, using 
different inhibitors, have shown that a decrease of IGF-1or IGF-1 signaling in VSMC is 
associated with reduced neointimal area size, suggesting the IGF-1 role in promoting 
vascular hyperplasia. In particular, targeted overexpression of IGF-1 in VSMC from carotid 
arteries increases neointimal formation (100). Che and collegues have demonstrated that 
IGF-1 enhanced basal TNF-α production and mRNA expression in cultured, bovine EC, 
suggesting a potential pro-inflammatory role of IGF-1 in early atherosclerotic lesions (101).  
Additionally, in atherosclerotic macrophages, IGF-1 promotes excess LDL uptake and 
cholesterol esterification as well as release of inflammatory cytokines and enhances their 
chemotactic macrophages migration (68, 69). 
1.9.2 IGF-1 in hypertension  
Several studies have investigated vascular effects of IGF-1 in hypertension (6). In 
fact, increased IGF-1 mRNA expression has been found in rat models of hypertrophying 
aorta, urinary bladder as well as portal vein (102). In addition, in a model of abdominal 
aortic coarctation hypertension, an increased IGF-1 mRNA and protein expression were 
detected (103), while a significantly elevated IGFBP-4 mRNA has been shown (104). In 
spontaneously hypertensive rats (SHR), impaired IGF-1 vasorelaxant properties were 
detected in norepinephrine pre-contracted thoracic aortic rings compared to normotensive 
(WKY) rings (73). Further evidence demonstrated a significant increase in arterial pressure 
in homozygous mice with a site-specific mutation in IGF-1 exon 3 (105), suggesting the 
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important role of IGF-1 in the regulation of blood pressure. Moreover, Tivesten and 
colleagues have observed an increase in peripheral resistance and systolic blood pressure in 
liver-specific IGF-1 knockout mice, suggesting IGF-1 involvement in regulation of blood 
pressure (79). Studies performed in patients with essential hypertension report elevated 
circulating levels of IGF-1, suggesting its involvement in pathophysiology of hypertension 
(81, 106).  
1.10 IGF-1 and transcriptional factors  
As described above, IGF-1, participates in progression of vascular remodelling 
through the activation of growth promoting and proliferative signaling pathways. 
Activation of multiple transcriptional factors plays an important role in vascular 
remodelling and IGF-1 has been shown to induce the expression of several genes in non-
vascular and vascular systems (107, 108). Among these transcriptional factors, the early 
growth response protein-1 (Egr-1) has been suggested to play an important role in 
regulating the transcription of several genes implicated in the development of vascular 
disease (109).  
1.11 Early growth response protein 1 (Egr-1) structure  
The early growth response protein (Egr) belongs to a group of DNA-binding zinc 
finger proteins that act as nuclear effectors of extracellular signals. Egr-1 was first 
discovered in a model for neuronal differentiation following the stimulation of PC-12 cells 
with neuronal growth factor (NGF) and consequently was assigned as nerve growth factor 
inducible A (NGFI-A) (110). Later, other laboratories also reported the existence of this 
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gene and variously named as zif268 (111), Krox24 (112) and TIS8 (113). Finally, during 
studies with human fibroblasts, Sukhatme and colleagues named this phosphoprotein, 
belonging to the C2H2 type zinc finger transcriptional factor, as Egr-1 (114). Mature Egr-1 
is a 80-82 kDa nuclear protein consisting of 533 amino acids in length. The Egr-1 gene is 
located on human chromosome 5q23-q31 and composed of two exons and one intron (115). 
Transcriptional factors are characterized by a modular structure, in other words, different 
functions, including DNA-binding, repression or transactivation of transcription can be 
attributed to different regions within the protein. The C-terminal region is rich in serine, 
threonine and proline, and the N-terminal contains only serine and threonine. The encoded 
Egr-1 protein consists of functionally independent domains that regulate Egr-1 transcription 
factor activity (Figure 1.4). The central DNA-binding domain (DBD), located between 
amino acids 332-416, consists of three zinc finger motives of the cysteine-histidine subtype 
(116). The zinc finger domain is represented as an alpha helix and an antiparallel beta-
pleated sheet. A bipartite nuclear localization sequence (NLS) of 15 amino acids on DBD 
N-terminal flanking region is also present in the structure of Egr-1 protein (117). Structural 
studies have determined a N-terminal strong activation domain (SAD) stretching from 
amino acids 3-281 and a weak activation domain (WAD) at the C-terminal (118). 
Additionally, a repressor domain (R), consisting of a conserved region of 34 amino acids 
residues,  has been mapped between the activation and DNA-binding domain and acts as a 
binding region for the transcriptional co-repressor proteins nerve growth factor-induced-A-
binding proteins 1 and 2 (NAB1 and NAB2) (119, 120). Egr-1 regulates the transcription of 
target genes by binding with high affinity via its zinc finger motives to the GC-rich DNA 
sequence 5’-GCGGGGGCG-3’ which is found in multiple target gene promoters, leading 
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to changes in target-gene expression (121), and therefore named Egr-1 binding sequence 
(EBS) (122). Following DNA binding, Egr-1 activates or represses gene transcription. 
 
 
Figure 1.4 Structure of inducible transcriptional factor Egr-1. 
A: Shematic representation of Egr-1 gene. Egr-1 consists of 5 independent domains, such 
as strong activation domain (SAD) promoting Egr-1 activity, a repressordomain (R), a 
nuclear localization site (NLS), a DNA-bindingdomain (DBD) containing 3 zinc fingers of 
the Cis2 Hist2 type and a weak activation domain (WAD) at the C-terminal (Gashleretal., 
1993). (Based on ref (119)).  
 
1.12 Egr-1 expression and regulation  
Egr-1 transactivation is increased through the interaction of transcriptional 
transactivators, including cyclic adenosine monophosphate (cAMP) response element-
binding protein (CREB), also known as CBP, and p300, and the activation region of 
Egr-1 (123). However, transcriptional activity of Egr-1 can also be negatively regulated 
by nuclear co-repressors NAB1 and NAB2 that bind to the inhibitory domain of Egr-1. 
In fact, deletion of repressor site induce a significant increase in Egr-1 transcriptional 
activity and overexpression of NAB1 resulted in its complete blockage (124). NAB1 is 
constitutively expressed at low level in most cell types, whereas NAB2 acts as an 
important factor induced by the same stimuli as Egr-1 and its expression is more tissue-
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selective. Therefore, NAB2 participates in a negative feedback by downregulating Egr-1 
activity (124). These co-repressors block the Egr-1-transcriptional activity via 
recruitment of the inhibitory nucleosomal remodelling and deacetylation (NuRD) 
complex, containing histone deacetylases 1 and 2 (HDAC1/2), to the Egr-1 promoter 
(125). The NAB2 expression is itself controlled by Egr-1, thereby enabling Egr-1 to 
regulate its own biological activity to avoid over-transactivation of target gene 
expression (126).  
As mentioned earlier, the regulation of Egr-1 is very complex. Numerous studies 
have investigated and characterized several functional motifs on Egr-1 promoter (Figure 
5). Egr-1 promoter contains two proximal and three distal serum response elements 
(SRE) with their adjacent Ets binding sites next to the 5’ TATA-box (127). SRE activity 
is mediated by two transcriptional factors, such as the serum response factor (SRF) and 
the ternary complex factor containing ETS domain-containing protein Elk-1 (Elk1), SRF 
accessory protein-1 or 2 (Sap1 or Sap2) proteins. In order to exhibit the biological 
activity, these two transcriptional factors bind to SRE. Elk1 protein is phosphorylated by 
MAPKs (JNK and ERK) leading to increased DNA binding, ternary complex formation 
as well as SRE-mediated transcriptional activation (128). Two cAMP response elements 
(CRE) are also located on the regulatory region of the human Egr-1 promoter. It has 
been shown that CRE may regulate Egr-1 gene transcription through the activation of 
SAPK2 signaling cascade (129). Furthermore, the Egr-1 promoter consists of two gene-
specific activator protein 1 (Sp1) binding sites, activator protein (AP1) and the EBS 
(130).  Interestingly, Egr-1 protein can downregulate the transcription of its own gene 
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via the EBS sequence (120). In addition, to transcriptional regulation, Egr-1 expression 
can also be controlled by post-translational modifications (122, 131). Acetylation, for 
instance, is one of Egr-1 post-translational modifications resulting in decreased Egr-1 
activity (132); however, phosphorylation (133) and sumoylation (134) are also reported 
to induce an increase in its expression.  
Egr-1 is expressed in different cell types. Among vascular cells that express Egr-1 
are endothelial cells, smooth muscle cells (SMC), fibroblast and leukocytes (124). Egr-1 
is activated in responses to a large number of stimuli, including growth factors 
hormones, neurotransmitters, shear stress and hypoxia. Following cell activation, Egr-1 
is expressed primarily in the nucleus and has been shown to regulate the transcription of 
several genes implicated in the pathogenesis of vascular disease (135).  
 
 
 
Figure 1.5 Regulatory regions of the human Egr-1 gene.  
The transcriptional start is indicated by the arrow. The 5’-flanking region contains a TATA 
box, several serum-response elements (SRE), a cyclic AMP response element (CRE), and 
proposed binding sites for transcription factors Sp1 and NF-kB. Moreover, Egr-1 binds to 
its own promoter via the EBS site. (Based on ref (120)). 
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1.13 Involvement of Egr-1 in cardiovascular pathophysiology  
Egr-1 has an extremely low or undetectable expression in the normal artery wall, but 
has been shown to be highly expressed in response to acute injury, growth factors, shear 
stress and hypoxia (124). Several studies have revealed an involvement of Egr-1 in wound 
healing, VSMC growth, migration, proliferation and intimal thickening (109, 124, 136). A 
large body of literature demonstrates an upregulation of Egr-1 expression at the endothelial 
wound edge following balloon catheter injury of the rat aorta (137). Santiago and 
colleagues provided the first direct evidence for the involvement of Egr-1 in wound healing 
through the local release of endogenous fibroblast growth factor-2 (FGF-2) by a paracrine 
activation of MAPKs signaling (138).  
Using a variety of gene-silencing approaches, it has been also shown that Egr-1 
contributes to SMC growth and intimal thickening in response to vascular injury. In fact, a 
growing body of evidence suggests that, during neointima formation in rat carotid arteries 
and in post-stent placement in pig coronary arteries, SMC proliferation and regrowth can be 
blocked by Egr-1 inhibition with antisense oligonucleotides (139-141). In accordance with 
these observations, in vitro study also demonstrated inhibition of neointimal formation in a 
rat model of balloon injury using a novel DNA enzyme ED5 that degrades Egr-1 mRNA 
(142, 143). In addition, significant reduction of neointima formation by at least 50% was 
observed in vein grafts of Egr-1 knockout mice compared to wild-type mice (144). 
Other studies provided further evidence for a role of Egr-1 in the development of 
vascular disease. In fact, Egr-1 expression was found to be significantly increased in 
atherosclerotic vessels compared to normal ones, where 5-fold higher expression of Egr-1 
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in human carotid lesions compared to adjacent tunica media was reported (145). It was 
suggested from these studies that the increased expression of Egr-1 in the atherosclerotic 
lesions was due to high level of Egr-1-target proinflammatory genes, such as TNFα, 
interleukine-2 (IL-2) and monocyte chemotactic protein-1 (MCP-1) that initiate early-stage 
atherosclerotic lesions (145). Another study in cells has also revealed increased Egr-1 
protein expression in human atherosclerotic lesions and tunica media (146). Furthermore, 
during hypercholesterolemia, elevated Egr-1 expression was also found in SMC of 
atherosclerotic lesions of fat fed low density lipoprotein receptor (LDLR)-null mice after 5 
weeks, and was progressively increased at 10 to 20 weeks (145). Similar observations were 
also made in apoE-deficient mice, suggesting an important role of Egr-1 in atherogenesis 
and lesion progression in human and mouse (147). Ghazvini-Boroujerdi and colleagues 
have also demonstrated an increased expression of Egr-1 in the pathogenesis of calcific 
aortic valve disease (148). It has been shown that Egr-1 is able to regulate multiple 
proinflammatory events that contribute to atherosclerotic process. For example, Egr-1 is 
found in inflammatory cells, such as CD68+ macrophages, of atherosclerosis lesions in 
fructose-fed LDLR deficient mice (animal model for atherosclerosis) (149). The ability of 
Egr-1 to induce an inflammatory response may be one of the mechanisms for its pro-
atherosclerotic effects.  
The implication of modified lipoproteins, a key factor in promoting atherogenic 
events, on Egr-1 expression has also been investigated. Experimental evidence suggested 
that oxidized lipoproteins such as oxidized low-density lipoprotein (oxLDL) upregulate 
Egr-1 expression via protein kinase C (PKC)/ERK pathways (150). PKC isoforms are 
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important upstream regulators of Egr-1 in response to vascular stress. PKCβ-mediated 
upregulation of Egr-1 results in vascular migration, proliferation and inflammation. In 
human VSMC, PKCβII pathway is crucial for LDL-induced cell proliferation (151). In fact, 
an in vivo study, has demonstrated that atherosclerotic lesions were significantly decreased 
in mice lacking both apoE and PKCβII compared to apoE-null mice (152). Collectively, 
these studies support the central role of Egr-1 in the development of vascular diseases and 
its involvement in a several signaling pathways. 
1.14 Goal of this study  
IGF-1 activates the expression of several genes linked to transcriptional factors 
involved in cell cycle control and inflammation. Egr-1 is a key transcriptional factor that 
plays an important role in vascular biology. Egr-1 has been shown to mediate gene 
transcription and its expression is upregulated in cardiovascular pathology, such as 
atherosclerosis, cardiac hypertrophy and ischemia. Moreover, Egr-1 expression is highly 
elevated in VSMC following vascular injury and has been suggested to regulate VSMC 
growth and intimal thickening. IGF-1 is a potent mitogen that has been implicated in 
pathophysiology of CVD through the activation of growth promoting and proliferative 
signaling pathways, such as MAPK and PI3-K/PKB in VSMC. However, no detailed 
studies on IGF-1-induced Egr-1 expression exist and the role of MAPK and PI3-K/PKB 
signaling pathways remains unexplored. Therefore, the goal of the present study is to 
investigate the involvement of MAPK, PI3-K/PKB signaling systems in IGF-1-induced 
Egr-1 expression.  
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Abstract 
Egr-1 is a transcription factor that plays an important role in vascular biology. Egr-1 
expression has been shown to be upregulated in cardiovascular disease (CVD). IGF-1, a 
potent mitogen and vasoactive factor, is believed to contribute to the development of CVD, 
such as atherosclerosis, through the hyperactivation of mitogenic and growth promoting 
pathways, including mitogen-activated protein kinase (MAPK) and protein kinase B (PKB) 
pathways, as well as regulation of multiple transcription factors. Reactive oxygen species 
(ROS) have been shown to mediate the effects of IGF-1 and is believed to contribute to the 
pathogenesis of vascular abnormalities. We have previously shown that IGF-1 can induce 
the expression of Egr-1 in VSMC; however, the signaling pathways involved in this 
process remain unexplored. Therefore, we have investigated the involvement of MAPK, 
PKB and ROS in IGF-1-induced Egr-1 expression. Treatment of VSMC with IGF-1 
enhanced Egr-1 protein levels in a time and dose-dependent fashion. Pharmacological 
blockade of RNA synthesis and protein synthesis by Actinomycine D and Cycloheximide, 
respectively, attenuated IGF-1-induced Egr-1 expression. AG1024, a selective 
pharmacological inhibitor of IGF-1R, also attenuated IGF-1-induced Egr-1 expression. 
Moreover, PD98059 and SP600125, two selective inhibitors of MEK/ERK1/2 and JNK 
family of MAPKs, respectively, significantly decreased IGF-1-stimulated increase in Egr-1 
expression in VSMC. In addition, pharmacological blockade of PI3K/PKB pathways by 
Wortmannin/SC-66 respectively, also attenuated IGF-1-induced Egr-1 expression. DPI 
(Diphenyleneiodonium), an NAD(P)H oxidase inhibitor, also blocked the Egr-1 expression 
in response to IGF-1. In summary, these data demonstrate that ERK1/2/JNK, PI3K/PKB 
and ROS-dependant signaling events play a critical role in IGF-1 induced expression of 
Egr-1 in VSMC (Supported by CIHR grants). 
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Introduction 
Aberrant proliferation, migration and growth of vascular smooth muscle cells (VSMC) are 
believed to be key events in vascular remodelling and contribute to the pathogenesis of 
vascular abnormalities such as atherosclerosis, hypertension and intimal thickening (1, 2). 
The involvement of growth factors and vasoactive peptides such as endothelin-1 and 
angiotensin-II in these processes has been well documented in the past decades. We have 
previously shown an involvement of insulin-like growth factor-1 receptor (IGF-1R) 
transactivation in triggering ET-1 and Ang-II-induced mitogenic and proliferative 
responses in VSMC (3, 4). IGF-1, a potent mitogen and vasoactive factor is known to 
induce structural alterations in the vessel wall by its ability to trigger proliferation, 
migration, hypertrophy and apoptosis of VSMC (1, 5-7). These cellular responses are 
induced through the activation of its tyrosine kinase receptor, IGF-1R (8) that is highly 
expressed in VSMC (9, 10). The signaling pathways induced by IGF-1R activation include 
mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase/protein kinase 
B (PI3-K/PKB) (5, 10-12) that lead to the regulation of the expression and the activity of 
multiple transcriptional factors and genes involved in vascular remodelling (13). The 
contribution of IGF-1R receptor signaling in vascular pathologies has been suggested and is 
supported by studies showing a significantly higher level of IGF-1 R concomitantly with 
increased signaling in VSMC isolated from the aorta of hypertensive animal models (14-
16). In addition, dominant-negative or antisense oligonucleotides of IGF-1R were also 
reported to attenuate neointimal thickening in injured carotid arteries (16, 17).  
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Early growth response protein 1 (Egr-1) is a zinc finger transcription factor, that is 
activated in responses to a large number of stimuli, including growth factors, vasoactive 
peptides, shear stress and hypoxia (13, 18-20). Egr-1 regulates the transcription of several 
genes implicated in the pathogenesis of vascular disease. It has been implicated in the 
development of atherosclerotic lesions and plays critical roles in regulating neointimal 
thickening in response to vascular injury and VSMC abnormal growth (21-23). Egr-1 
expression is highly upregulated in atherosclerotic vessels as compared to normal vessels 
(24). In injured arteries, Egr-1 expression has also been shown to be rapidly and transiently 
increased in both endothelial cells and VSMC (25). In parallel, studies have demonstrated 
the inhibitory effect of Egr-1 knockout during neointima formation in rat carotid arteries as 
well as in vein graft, suggesting its critical role in vessel damage (13, 26). We have recently 
demonstrated that Egr-1 expression is upregulated in response to IGF-1 in VSMC (16, 19). 
However, the signaling pathways implicated in IGF-1-induced Egr-1 expression in VSMC 
remain poorly characterized. In this study, we have investigated the involvement of MAPK 
and PI3-K/PKB signaling pathway, as well as ROS generation in transducing the effect of 
IGF-1 on Egr-1 expression in VSMC. 
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Materials and Methods 
 
Antibodies and reagents: 
IGF-1 was obtained from Peprotech Inc and cell culture reagents were procured from 
Invitrogen Corp. (Grand Island, New York). AG1024 (IGF-1R inhibitor), PD98059 (MEK 
inhibitor), SP600125 (JNK inhibitor), Wortmannin (PI3-K inhibitor), SC-66 (AKT 
inhibitor XVIII) and DPI (NAD(P)H oxidase  inhibitor) were purchased from Calbiochem 
(San Diego, California). Phospho-Ser473-specific-PKB, anti-PKB,  phospho- Thr183/Tyr185-
specific-JNK, anti-JNK, Egr-1, β-tubulin and anti-rabbit antibodies were from Cell 
Signaling (Beverly, Massachusetts, USA), and phospho-Thr202/Tyr204-specific-ERK1/2 
horseradish peroxidase-conjugated goat anti-mouse immunoglobulin antibodies were from 
Santa Cruz Biotechnology (Santa Cruz, Calif.). The enhanced chemiluminescence (ECL) 
detection system kit was procured from Perkin Elmer (Montreal, QC). 
 
Cell culture: 
A-10 VSMC derived from thoracic aorta of embryonic rat were maintained in culture with 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin, in a humidified atmosphere of 5% CO2 exchange at 37oC. 
They were sub-cultured twice a week by harvesting them with 
trypsin/ethylenediaminetetraacetic acid (EDTA). The cells were grown to 80-90% 
confluence in 60-mm culture plates and incubated in serum-free DMEM 5 hours prior to 
treatment.  
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Cell lysis and Immunoblotting: 
Confluent, serum-starved quiescent A-10 VSMC were pre-treated in the presence of 
various agents for 30 min,  followed by stimulation with 6.5nmol/L IGF-1 for 1 h. Then 
cells were washed twice with ice-cold PBS and lysed in 200μl of buffer (25 nmol/L Tris-
HCl, pH 7.5. 25 mmol/L NaCl, 1 mmol/L Na orthovanadate, 10 mmol/L Na fluoride, 10 
mmol/L Na pyrophosphate, 2 mmol/L benzamidine, 2 mmol/L ethylenebis 
(oxyethylenenitrilo)-tetraacetic acid (EGTA), 2 mmol/L ethylenediamine-tetraacetic acid 
(EDTA), 1 mmol/L phenylmethylsulphonyl fluoride (PMSF), 10 μg/ml aprotinin, 1% 
Triton X-100, 0.1% sodium dodecyl sulfate (SDS) and 0.5 μg/ml leuleptin) on ice. The cell 
lysates were centrifuged and clarified by centrifugation at 12000g for 10 min at 4oC. 
Protein concentrations were determined by Bradford assay. Equal amounts of protein were 
subjected to either 7.5% or 10% sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE), transferred to polyvinylidine difluoride (PVDF) membranes 
(Millipore, USA) and incubated overnight at 4oC with respective primary antibodies Egr-1 
(1:1000), and β-tubulin (1:8000). The antigen-antibody complex was detected by 
horseradish peroxidase-conjugated secondary antibody (1:4000), and protein bands were 
visualized by ECL. The same blots were subsequently reprobed with corresponding total 
antibodies to detect the total amount of these proteins. The intensity of the bands was 
quantified by densitometric analysis using Quantity One Bio-Rad Corp. imaging and 
Graphpad Prism 5 (San Diego, CA, USA) software programs.  
 
 
 
34 
 
 
 
 
Preparation of the nuclear fraction: 
Cells incubated in the absence or presence of various agents were washed twice with ice-
cold PBS and lysed in 200μl of buffer solution containing 10 mmol/L Hepes, 10 mmol/L  
KCl, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 1 mmol/L PMSF, 1 mmol/L protease cocktail 
inhibitor and 1 mmol/L Na orthovanadate. The cells lysates were vortexed for 10 s at 
highest setting after adding NP40 10% detergent and were centrifuged at 18327g for 4 min 
at 4oC. The pellet was resuspended in 60 μL of buffer containing 10 mmol/L Hepes, 400 
mmol/L NaCl, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 1 mmol/L PMSF, 1 mmol/L 
protease cocktail inhibitor and 1 mmol/L Na orthovanadate. The suspension was sonicated 
for 6 cycles at 10 s per cycle with 30 s intervals between each cycle and then centrifuged at 
18327g for 5 min at 4oC. The pellet was discarded and the supernatant, which corresponds 
to the nuclear fraction, was collected. The protein content in the nuclear fraction was 
determined by Bradford assay and equal amounts of protein were subjected to SDS-PAGE 
and immunoblotted using Egr-1 antibodies. 
 
 
Statistics: 
Statistical analysis was performed by one-way, standard analysis of variance (ANOVA) 
followed by a Tukey post hoc test. All data are reported as means ± SE. The differences 
between means were considered significant at P < 0.05. 
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Results 
IGF-1 induces rapid increase in Egr-1 expression in dose and time-dependent fashion 
through the IGF-1R in A10 VSMC 
 
Egr-1, a zinc finger transcription factor, plays a critical role in cardiovascular 
pathobiology (28). However, the effect of IGF-1 on Egr-1 expression in VSMC has not 
been characterized in details; therefore, we investigated the response of IGF-1 on Egr-1 
expression in A10 aortic VSMC. As shown in Fig. 1A, treatment of VSMC with IGF-1 
induced the expression of Egr-1 in a dose-dependent manner and a significant increase in 
Egr-1 level was detected at 0.65 nmol/L IGF-1, the lowest dose tasted. Further increasing 
the IGF-1 concentration led to a more robust increase in Egr-1 expression and at 6.5 
nmol/L, there was about 25 fold increase in Egr-1 expression compared to control cells. 
Moreover, IGF-1-induced expression of Egr-1 was time-dependent; however, Egr-1 
expression could be detected only after the stimulation of cells for 60 min, which was 
significantly reduced after the treatment for 90 min (Fig. 1B). Therefore, all further 
experiments were carried out with cells treated with 6.5 nmol/L of IGF-1 for 60 min. In 
order to confirm the involvement of IGF-1R in IGF-1-induced increase in Egr-1 expression, 
we used AG1024, a highly specific inhibitor that blocks IGF-1R tyrosine kinase activity. 
As depicted in Fig.2, a marked inhibition of Egr-1 expression was observed in cells treated 
with 10μM AG1024 compared to VSMC treated with IGF-1 alone. These results 
demonstrate that IGF-1 acts through its IGF-1R to upregulate Egr-1 expression in VSMC.  
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IGF-1 upregulates Egr-1 in A10 VSMC 
 
Growth factors modulate protein expression by acting either on translational process 
leading to protein synthesis or by acting at the transcriptional level leading to changes in 
mRNA synthesis. In order to test whether the upregulation of Egr-1 in response to IGF-1 is 
the result of enhanced mRNA or protein synthesis, we used Actinomycin D (A) and 
Cycloheximide (B); two compounds that specifically target and inhibit RNA synthesis by 
complexing with DNA via deoxyguanosine residues thereby preventing the elongation of 
RNA chains (29) and protrin synthesis by blocking translation of mRNA on cytosolic 80S 
ribosomes (30), respectively. As shown in Fig. 3A, treatment of VSMC with Actinomycin 
D, prior to stimulation with IGF-1, resulted in a dose-dependent inhibition of Egr-1 
expression. Similarly, Cycloheximide (Fig. 3B), a known inhibitor of protein synthesis, 
also markedly attenuated IGF-1-induced Egr-1 expression in VSMC by about 60% at 
100ng/ml; however it appeared to be slightly less potent than the inhibitory effect of 
Actinomycin D on IGF-1-induced Egr-1 expression.  
 
IGF-1-induced Egr-1 expression via MAPKs pathways in A10 VSMC 
 
Since IGF-1 has been shown to activate MAPK signaling pathways (5, 10) and 
because MAPK pathways are known to regulate Egr-1 expression in different cell types of 
non-vascular origin (31, 32), we hypothesized that IGF-1 upregulates Egr-1 expression 
through MAPK signaling cascades. To confirm this and in order to identify which of these 
MAPKs are implicated in IGF-1-induced Egr-1 expression, PD98059 and SP600125 two 
specific pharmacological inhibitors of MEK/ERK1/2 and JNK pathways respectively were 
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used. As shown in Fig.4A, Egr-1 expression was strongly enhanced by IGF-1, and 
PD98059 treatment dose-dependently attenuated this effect, with a marked attenuation of 
about 80% observed at 5 μM and almost complete inhibition of Egr-1 expression was 
detected at 10 μM. In addition, pre-treatment of A10 VSMC with SP600125 prior to 
stimulation with IGF-1 also dose-dependently decreased Egr-1 expression (Fig.4B). This 
indicated the involvement of both MEK/ERK and JNK pathways in IGF-1-induced Egr-1 
expression in VSMC.  
 
Activation of PI3-K/PKB pathways is required for IGF-1-induced Egr-1 expression in 
A10 VSMC 
 
The implication of PI3-K/PKB pathways in triggering some signaling responses of 
IGF-1 has been well documented (11, 33). In addition, PKB pathway is known to modulate 
the protein synthesis and activity of the transcriptional factors through its multiple 
downstream targets, including p70S6K and elF4E in multiple cell types (34). However, 
involvement of the PKB in mediating IGF-1-induced Egr-1 expression in VSMC has not 
been examined. Therefore, to investigate whether PI3-K/PKB pathway participates in IGF-
1-induced Egr-1 expression, we used Wortmannin (PI3-K inhibitor) (35) and SC-66 (PKB 
inhibitor) (36). As shown in Fig.5A, 100nM of Wortmannin caused a significant reduction 
in Egr-1 expression induced by IGF-1. Consistent with the results shown in Fig.5A, pre-
treatment of A10 VSMC with SC-66 also dose-dependently inhibited IGF-1-induced Egr-1 
expression. In fact, a significant inhibitory effect of SC-66 could be detected at 1 μM, 
representing 40% of inhibition; however, higher concentrations of this antagonist exerted a 
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more robust inhibitory effect and almost completely attenuated the Egr-1 expression 
induced by IGF-1 (Fig.5B). These data demonstrates that IGF-1-induced Egr-1 expression 
requires PI3-K/PKB pathways in VSMC.    
 
Activation of ROS pathways is required for IGF-1-induced signaling and Egr-1 
expression in A10 VSMC 
 
ROS are believed to contribute to the pathogenesis of vascular abnormalities. IGF-1 has 
been reported to mediate many of its responses through the activation of NAD(P)H oxidase 
derived generation of ROS (37, 38). However, a role of ROS in IGF-1-induced Egr-1 
expression in VSMC remains unexplored, therefore by using diphenyleneiodonium (DPI), a 
NAD(P)H oxidase inhibitor, we investigated whether ROS is involved in Egr-1 expression 
in response to IGF-1. As depicted in Fig.6. DPI pre-treatment markedly reduced IGF-1-
induced Egr-1 expression in VSMC. Interestingly, DPI treatment of VSMC also resulted in 
the attenuation of IGF-1 induced phosphorylation of PKB (Fig. 7A), ERK1/2 (Fig. 7B), and 
JNK (Fig. 7C) in VSMC. These data confirm the involvement of ROS generation in IGF-
induced signaling, as well as in IGF-1-induced Egr-1 expression in A10 VSMC. 
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Discussion 
In the present work, we have identified the intracellular signaling pathways 
involved in IGF-1-induced Egr-1 expression. By using PD98059 and SP600125, specific 
pharmacological inhibitors of ERK1/2 and JNK respectively, we demonstrate the 
involvement of the MAPKs in IGF-1-induced Egr-1 expression in VSMC. We show that 
inhibition of any of these MAPKs is sufficient to turn-off the stimulatory effect of IGF-1 on 
Egr-1 expression in A10 VSMC. A similar role of ERK1/2 and JNK pathways in inducing 
hydrogen-peroxide (H2O2)-, lipopolysaccharide (LPS)- and lysophophatidic acid (LPA)-
induced Egr-1 expression in cardiomyocytes, human monocytic cells and VSMC 
respectively, have been reported (39-41). A role of ERK1/2 pathway in the upregulation of 
Egr-1 expression by Apelin-13, a ligand for G protein coupled receptor, as well as by TNF-
α has also been demonstrated in VSMC (42, 43). An involvement of ERK/JNK dependent 
mechanism in mediating Egr-1 expression in non-vascular cells in response to epidermal 
growth factor (EGF) (44) and silica dust has also been reported (45). These findings 
underscore the importance of MAPKs pathways in transducing the signals of various 
stimuli leading to the enhanced expression of Egr-1.  
In addition, our data showing that pharmacological blockade of PI3-K by 
Wortmannin or PKB by SC-66 almost completely attenuated the enhanced expression of 
Egr-1 in response to IGF-1 implicated the PI3-K/PKB signaling cascade as an upstream 
regulator of Egr-1 expression in VSMC. Previous data have shown a role of PI3-K in 
insulin-induced Egr-1 expression in rat fibroblasts (46) and in integrin-induced Egr-1 
expression in endothelial cells (47). However, to the best of our knowledge, the work 
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presented here is the first to report an involvement of MAPK and PI3-K/PKB signaling 
events in modulating Egr-1 expression in response to IGF-1 in VSMC. 
Our studies showing that pharmacological blockade of NAD(P)H oxidase by DPI 
significantly attenuated Egr-1 expression in response to IGF-1 in VSMC, support the notion 
that ROS generation is a key trigger to induce Egr-1 expression in response to IGF-1. The 
fact that DPI treatment also inhibited the phosphorylation of ERK1/2/JNK and PKB, 
indicated that ROS acts upstream of these signaling molecules in IGF-1-induced pathways 
leading to Egr-1 expression in VSMC. A role of ROS generated by NAD(P)H oxidase 4 
(NOX4) in inducing the signaling responses as well as the proliferative and migratory 
responses of IGF-1 in VSMC has been reported earlier (48). In accordance with the present 
results, previous studies have also shown the involvement of ROS generation in Egr-1 
induction in response to xanthine oxidase (XO) in pulmonary artery smooth muscle cells 
(49). Hemin has also been reported to induce Egr-1 expression via the ROS/ERK pathways 
in human aortic VSMC (50). Taken together, these data demonstrate that ROS generation is 
required in IGF-1-induced Egr-1 expression. 
Recent studies have reported a role of c-Jun in shear and injury-induced Egr-1 
expression in VSMC (51). Since c-Jun is a downstream target of JNK, it may be suggested 
that IGF-1-induced phosphorylation of JNK contributes to enhanced transcription of Egr-1 
via c-Jun in VSMC. Elk-1 is a downstream effector of ERK1/2 and is activated by ERK-
mediated phosphorylation (52). Hemin was recently shown to induce the expression of Egr-
1 in Elk-1 dependent fashion (50). It is thus possible that IGF-1 induced ERK1/2 
phosphorylation via Elk-1 activation is also responsible for IGF-1-induced Egr-1 
expression in VSMC.  
41 
 
 
 
 
Egr-1 is an important transcription factor involved in the pathogenesis of several 
cardiovascular disorders (28). Its ability to regulate the transcription of several genes linked 
with the cell cycle has been attributed towards its pathogenic roles (21). IGF-1 system has 
been implicated in vascular pathologies and the levels of IGF-1R or signaling has been 
reported to be heightened in aorta of hypertensive animal models (14, 15). Moreover, 
dominant negative IGF-1R or antisense oligonucleotide of IGF-1R has been shown to 
inhibit neointimal formation in an injured carotid artery rat model (17). These results 
suggest that the ability of IGF-1 to enhance the expression of Egr-1 in VSMC may be one 
of the mechanisms by which IGF-1 exerts its deleterious effect in the vascular system.  
In summary, our data have demonstrated the involvement of ERK1/2, JNK, PI3-
K/PKB as well as ROS, as upstream regulators of Egr-1 expression in response to IGF-1. 
Since MAPK and PI3-K/PKB signaling pathways have been shown to be upregulated in 
vascular pathologies and ROS generation contribute to vascular abnormalities, it may be 
suggested that exaggerated expression of Egr-1 detected in vascular diseases such as 
atherosclerosis, may be caused by hyperactivation of these signaling cascades. 
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Figure Legends 
 
Figure 1. Insulin-like growth factor-1 (IGF-1) enhances early growth response protein 
1 (Egr-1) expression in A10 vascular smooth muscle cells (VSMC) in a time and dose-
dependent fashion.  
Serum-starved quiescent A-10 VSMC were treated in the absence (CTL) or presence of 
6.5nmol/L IGF-1 for indicated times (B), or with increasing doses of IGF-1 for 60 min (A). 
Nuclear fractions of the cells lysates were probed with Egr-1 antibody (top panels) and also 
analyzed for protein loading using β-tubulin (middle panels). Bar diagrams (bottom panels) 
represent the densitometric quantifications of Egr-1 relative to β-tubulin. Values are the 
means ± SE of 3 independent experiments and expressed as a ratio where the control values 
are taken as 1. **P<0.005 and ***P<0.0005, compared to CTL.  
 
Figure 2. Attenuation of Insulin-like growth factor-1 (IGF)-1-induced early growth 
response protein 1 (Egr-1) expression by AG1024 (IGF-1R-PTK inhibitor) in A10 
vascular smooth muscle cells (VSMC) in a dose-dependent fashion 
Serum-starved quiescent A-10 VSMC were pre-treated with (5μM) or without (0) AG1024 
(IGF-1R-PTK inhibitor) for 30 min, followed by stimulation with 6.5nmol/L IGF-1 for 1 h. 
Nuclear fractions of the cells lysates were probed with Egr-1 antibody (top panel) and also 
analyzed for protein loading, using β-tubulin (middle panel). Bar diagrams (bottom panels) 
represent the densitometric quantifications of Egr-1 relative to β-tubulin. Values are the 
means ± SE of at 3 independent experiments and expressed as a ratio where the control 
values are taken as 1. ** P<0.005 compared with the control VSMC; ##P<0.005 compared 
to VSMC treated with IGF-1 alone. 
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Figure 3. Attenuation of Insulin-like growth factor-1 (IGF)-1-induced early growth 
response protein 1 (Egr-1) expression by Actinomycine D (DNA synthesis inhibitor) 
and Cycloheximide (protein synthesis inhibitor) in A10 vascular smooth muscle cells 
(VSMC) in a dose-dependent fashion  
 
Confluent, serum-starved quiescent A-10 VSMC were pre-treated with (50ng/ml, 100ng/ml 
and 200ng/ml) or without (0) Actinomicyne D (protein synthesis inhibitor) (A) and 
Cycloheximide (DNA synthesis inhibitor) (B) for 30 min, followed by stimulation with 
6.5nmol/L IGF-1 for 1 h. Nuclear fractions of the cells lysates were probed with Egr-1 
antibody (top panels) and also analyzed for protein loading, using β-tubulin (middle 
panels). Bar diagrams (bottom panels) represent the densitometric quantifications of Egr-1 
relative to β-tubulin. Values are the means ± SE of at 3 independent experiments and 
expressed as a ratio where the control values are taken as 1. *** P<0.0005 compared with 
the control VSMC; ###P<0.05 compared to VSMC treated with IGF-1 alone.  
 
Figure 4. Attenuation of Insulin-like growth factor-1 (IGF)-1-induced early growth 
response protein 1 (Egr-1) expression by PD98059 (MEK1/2 inhibitor) and SP600125 
(JNK inhibitor) in A10 vascular smooth muscle cells (VSMC) in a dose-dependent 
fashion 
Confluent, serum-starved quiescent A-10 VSMC were pre-treated with (1μM, 5μM and 
10μM) or without (0) PD98059 (MEK1/2 inhibitor) (A) and SP600125 (JNK inhibitor) (B) 
for 30 min, followed by stimulation with 6.5nmol/L IGF-1 for 1 h. Nuclear fractions of the 
cells lysates were probed with Egr-1 antibody (top panels) and also analyzed for protein 
loading, using β-tubulin (middle panels). Bar diagrams (bottom panels) represent the 
densitometric quantifications of Egr-1 relative to β-tubulin. Values are the means ± SE of at 
3 independent experiments and expressed as a ratio where the control values are taken as 1. 
*** P<0.0005 compared with the control VSMC; #P<0.05 compared to VSMC treated with 
IGF-1 alone.  
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Figure 5. Attenuation of Insulin-like growth factor-1 (IGF)-1-induced early growth 
response protein 1 (Egr-1) expression by Wortmannin (PI3-K inhibitor) and SC-66 
(PKB inhibitor) in A10 vascular smooth muscle cells (VSMC) in a dose-dependent 
fashion 
Confluent, serum-starved quiescent A-10 VSMC were pre-treated with either Wortmannin 
(PI3-K inhibitor) (A) or SC-66 (PKB inhibitor) (B) for 30 min at indicated concentrations, 
followed by stimulation with 6.5nmol/L IGF-1 for 1 h. Nuclear fractions of the cells lysates 
were probed with Egr-1 antibody (top panels) and also analyzed for protein loading, using 
β-tubulin (middle panels). Bar diagrams (bottom panels) represent the densitometric 
quantifications of Egr-1 relative to β-tubulin. Values are the means ± SE of at 3 
independent experiments and expressed as a ratio where the control values are taken as 1. 
** P<0.005 compared with the control VSMC; #P<0.05 compared to VSMC treated with 
IGF-1 alone.  
 
Figure 6. Attenuation of Insulin-like growth factor-1 (IGF)-1-induced early growth 
response protein 1 (Egr-1) expression by DPI (NADPH oxidase inhibitor) in A10 
vascular smooth muscle cells (VSMC) in a dose-dependent fashion 
Confluent, serum-starved quiescent A-10 VSMC were pre-treated with DPI (NADPH 
oxidase inhibitor) for 30 min at indicated concentrations, followed by stimulation with 
6.5nmol/L IGF-1 for 1 h. Nuclear fractions of the cells lysates were probed with Egr-1 
antibody (top panels) and also analyzed for protein loading, using β-tubulin (middle 
panels). Bar diagrams (bottom panels) represent the densitometric quantifications of Egr-1 
relative to β-tubulin. Values are the means ± SE of at 3 independent experiments and 
expressed as a ratio where the control values are taken as 1. ** P<0.05 compared with the 
control VSMC; #P<0.05 compared to VSMC treated with IGF-1 alone. 
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Figure 7. Effect of the NAD(P)H oxidase inhibitor (DPI) on Insulin-like growth factor-
1 (IGF-1)-induced PKB, ERK1/2 and JNK phosphorylation in A10 vascular smooth 
muscle cells (VSMC)  
Confluent, serum-starved quiescent A-10 VSMC were pre-treated with DPI (NADPH 
oxidase inhibitor) for 30 min at10μM, followed by stimulation with 6.5nmol/L IGF-1 for 
indicated times. Cell lysates were probed by phosphor-specific-Ser473-PKB antibody (A), 
phosphor-specific Thr202/Tyr204-ERK1/2 antibody (B) or phosphor-specific Thr183/Tyr185-
JNK antibody (C), (top panels). Blots were also analyzed for total PKB, ERK1/2 or JNK 
(middle panels). Bar diagrams (bottom panels) represent the quantifications of 
phosphorylated p-PKB relative to total PKB (A), phosphorylated p-ERK1/2 relative to total 
ERK (B) or phosphorylated p-JNK relative to total JNK (C). Values are the means ± SE of 
at 3 independent experiments and expressed as a ratio where the control values are taken as 
1. ** P<0.005 compared with the control VSMC; # P<0.5 compared to VSMC treated with 
IGF-1 alone. 
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DISCUSSION GÉNÉRALE 
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The contribution of aberrant VSMC proliferation and migration in the pathogenesis 
of cardiovascular disease has been broadly documented. Alterations in these physiological 
events in VSMC in response to hormonal or physical stimuli underlie the progression of 
vascular diseases such as atherosclerosis and hypertension. IGF-1 and various other growth 
factors have been demonstrated to trigger multiple signaling pathways that induce 
transcriptional events implicated in vascular remodeling. In the cardiovascular system, IGF-
1 is secreted and synthesized by vascular cells and consequently may exert both endocrine 
and autocrine/paracrine actions on VSMC. The mitogenic responses of IGF-1 are mediated 
through the IGF-1R, a transmembrane tyrosine kinase that is abundantly expressed in 
VSMC. Upon activation of IGF-1R, two main signaling pathways are stimulated that 
regulate the growth promoting properties of IGF-1. First, signaling pathway is comprised of 
the mitogen activated protein kinase (MAPK) involving the extracellular signal-regulated 
kinase 1/2 (ERK1/2), the p38-MAPK and c-jun-NH2-terminal kinase (JNK). These 
molecules have been largely demonstrated to participate in several cellular events that lead 
to aberrant growth, migration, and cell fate. Hyperactivation of these signaling molecules is 
an accepted hallmark of vascular abnormalities as observed in various experimental models 
of atherosclerosis and hypertension. Several cytosolic proteins and transcription factors are 
targeted by phosphorylated ERK1/2 either in the cytosol or following translocation to the 
nucleus. Activation of Elk1, serum response factor (SRF), ATF2 and Jun involved in 
immediate early gene transcription (153, 154) downstream of ERK1/2 activation is a good 
example of this activity. In parallel, phophatidyl-inositol 3-kinase/protein kinase B (PI3-
K/PKB) is the second well-known pathway that is triggered following IGF-1R activation in 
the vasculature. In fact, by modulating the activities of multiple downstream targets such as 
mammalian target of rapamycin (mTOR), glycogen synthase kinase-3 (GSK-3), p70 
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ribosomal S6 kinase (p70s6k), forkhead box protein (FOXO), this pathway has been shown 
to regulate the expression of various proteins implicated in atherosclerosis and 
hypertension. PKB also modulates cellular fate through its anti-apoptotic properties 
involving the activation of Bcl-2-associated death promoter (Bad) (155). Several studies 
have supported a critical role of aberrant IGF-1R signaling in vascular pathologies. In fact, 
a significantly higher expression and function of IGF-1R in VSMC isolated from the aorta 
of spontaneously hypertensive rats (SHR) has been suggested (11, 12). In addition, 
dominant negative or antisense oligonucleotides (ASO) of IGF-1R have been reported to 
reduce neointima formation of injured rat’s carotid arteries (14). Moreover, as reported 
from earlier studies, IGF-1 has been shown to induce ROS generation through the 
activation of NADPH oxidase 4 (NOX-4), and many of the responses of IGF-1 have been 
reported to be attenuated by blocking NOX-4 expression (156-158).  
In the context of vascular diseases, several lines of evidence have reported an 
overexpression of Egr-1 in different models such as wound healing following balloon 
catheter injury of the rat aorta (137), and intimal thickening due to VSMC growth, 
migration, proliferation and hypertrophy (109, 136). Increased expression of Egr-1 in 
atherosclerotic lesions has been linked to inflammatory markers that may initiate early-
stage atherosclerotic lesions. TNFα, interleukin-2 (IL-2) and monocyte chemotactic 
protein-1 (MCP-1) were therefore proposed to be targets of Egr-1 activity (145). However, 
despite this large body of literature, the effect of IGF-1 on Egr-1 expression in VSMC 
remains unclear and the pathways that link IGF-1 to Egr-1 expression still need to be 
unravelled.   
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 In these studies, we examined the effect of IGF-1 on Egr-1 expression in VSMC 
and we elucidated the involvement of MAPK pathway, PI3-K/PKB pathway and ROS 
generation in this response. We found a dose and time-dependent increase of Egr-1 
expression in response to IGF-1. Moreover, we observed that pharmacological blockade of 
RNA synthesis and protein synthesis by Actinomycine D and Cycloheximide, respectively, 
decreased IGF-1-induced Egr-1 expression. In addition, our data is the first to report 
inhibitory effects of different selective MAPKs, PI3-K/PKB and ROS generation inhibitors 
on IGF-1-induced Egr-1 expression.   
Taken together, our results demonstrated the involvement of MAPKs, PI3-K/PKB 
pathways and ROS generation in IGF-1-stimulated increase in Egr-1 expression in A-10 
VSMC. Because IGF-1 induces a marked increase of Egr-1 expression in VSMC through 
the activation of growth promoting signaling pathways, it may provide important insights 
on vascular remodeling, as well as introduce new targets in order to treat or prevent 
vascular abnormalities.  
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The findings in the present study demonstrate for the first time the requirement of MAPKs, 
PI3-K/PKB pathways, as well as ROS generation in mediating IGF-1-induced Egr-1 
expression in A-10 VSMC. These results were obtained by using PD989059, SP600125, 
Wortmannin, SC-66 and DPI, specific pharmacological inhibitors of ERK1/2, JNK, PI3-K, 
PKB, as well as NAD(P)H oxidase, respectively.  
IGF-1 has been suggested to play an important role in the pathogenesis of vascular 
diseases. However, the precise mechanism by which IGF-1 exerts its detrimental responses 
in vascular dysfunction remains to be unravelled. Since IGF-1 enhanced the expression of 
Egr-1 and its upregulation triggers proliferative and growth promoting signaling pathways, 
it may be suggested that one of the possible mechanisms by which IGF-1 contributes to its 
deleterious responses in the vasculature is via this pathway (Figure 1.6). Even though our 
findings identify for the first time the signaling pathways involved in IGF-1-induced Egr-1 
expression in VSMC, further studies are required to elucidate the precise mechanism by 
which IGF-1 enhances Egr-1 expression in order to develop new therapeutical targets in the 
context of cardiovascular disease.  
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Figure 1.6 Schematic model of signaling pathways involved in IGF-1-induced Egr-1 
expression in A10 vascular smooth muscle cells (VSMC)  
Activation of IGF-1R phosphorylates multiple downstream targets, leading to the 
phosphorylation and activation of the MAPKs, such as ERK1/2, JNK and p38, as well as 
PI3-K/PKB/AKT signaling pathways. This results in regulation of the expression of 
multiple transcriptional factors, including Egr-1. ERK1/2 pathway contributes to gene 
transcription, cell growth and hypertrophy, whereas PI3-K/PKB/AKT signaling pathway 
increases protein synthesis and regulates cell survival and proliferation. Early growth 
response protein 1 (Egr-1); Insulin-like growth factor-1(IGF-1); Insulin-like growth factor-
1 receptor (IGF-1R); Extracellular regulated kinase 1 and 2 (ERK1/2); c-Jun N-terminal 
kinase (JNK); Protein kinase B (PKB); Phosphoinositide 3- kinase (PI3-K); p 
(phosphorylated).  
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